ALISO VIEJO, CA, SpyGlass Pharma, a company developing a treatment for glaucoma and other chronic ophthalmic diseases, announced a $90 million Series C funding round.
SpyGlass Pharma, a company developing a treatment for glaucoma and other chronic ophthalmic diseases, announced a $90 million Series C funding round led by RA Capital Management alongside existing investors New Enterprise Associates and Vensana Capital, as well as new investors Samsara BioCapital and Vertex Ventures HC.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
